

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/582,705
		Filing Date	June 12, 2006
		First Named Inventor	John Foekens
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 1 of 6	Attorney Docket Number	47675-198	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ¹ (if known)			
/JS/		US- 5574142	11-12-1996	Meyer, Jr. et al.	
		US- 5585481	12-17-1996	Arnold, Jr. et al.	
		US- 5587371	12-24-1996	Sessler et al.	
		US- 5597696	01-28-1997	Linn et al.	
		US- 5744305	04-28-1998	Fodor et al.	
		US- 5786146	07-28-1998	Herman et al.	
		US- 5837832	11-17-1998	Chee et al.	
		US- 5958773	09-28-1999	Monia et al.	
		US- 6265171	07-24-2001	Herman et al.	
		US- 6331393	12-18-2001	Laird et al.	
		US- 6596488	07-22-2003	Pfeifer et al.	
		US 2003/0013091	01-16-2003	Dimitrov	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/JS/		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 97/45560	12-04-1997	North Shore University Hospital Research Corp.		
		WO 97/46705	12-11-1997	Johns Hopkins University School of Medicine		
		WO 99/28498	06-10-1999	Epigenomics GMBH		
		WO 02/38801	05-16-2002	Human Genetic Signatures Pty Ltd		
		WO 02/059347	08-01-2002	Johns Hopkins University School of Medicine		

Examiner Signature	/Jehanne Sitton/	Date Considered	10/18/2010
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/582,705
		Filing Date	June 12, 2006
		First Named Inventor	John Foekens
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2 of 6	Attorney Docket Number	47675-198	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 2004/000463	12-31-2003	Epigenomics AG		
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		BELYAVSKY et al., "PCR-based cDNA library construction: general cDNA libraries at the level of a few cells," Nucleic Acids Research, 1989, pp. 2919-2932, Volume 17, No. 8				
		BERNS et al., "Predictive value of SRC-1 for taxomifen response of recurrent breast cancer," Breast Cancer Research and Treatment, 1998, pp. 87-92, Volume 48				
		BIECHE et al., "The CGA gene as new predictor of the response to endocrine therapy in ERo-positive menopausal breast cancer patients," Oncogene, 2001, pp. 6955-6959, Volume 20				
		BIECHE et al., "Identification of CGA as a Novel Estrogen Receptor-responsive Gene in Breast Cancer: An Outstanding Candidate Marker to Predict the Response to Endocrine Therapy," Cancer Research, February 15, 2001, pp. 1652-1658, Volume 61				
		CIOCCA et al., "Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients," Endocrine, August 2000, pp. 1-10, Volume 13, No. 1				
		CURRAN et al., "Quality of Life of Early-stage Breast Cancer Patients Treated with Radical Mastectomy or Breast-conserving Procedures: Results of EORTC Trial 10801," European Journal of Cancer, February 1998, pp. 307-314, Volume 34, No. 3				
		DATABASE EMBL, "1M0228A10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0228A10 F, DNA sequence," XP002324932, October 6, 2000, retrieved from EBI accession no. EM PRO:AZ438069, Database accession no. AZ438069, Abstract				
		DU et al., "Discrepancy between consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer," Annals of Internal Medicine, January 2003, pp. 90-98, Volume 138, No. 2				
		EADS et al., "CpG Island Hypermethylation in Human Colorectal Tumors Is Not Associated with DNA Methyltransferase Overexpression," Cancer Research, May 15, 1999, pp. 2302-2306, Volume 59				
		ELLEDGE et al., "bcl-2, p53, and Response to Tamoxifen in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study," Journal of Clinical Oncology, May 1997, pp. 1916-1922, Volume 15, No. 5				
		FARCZADI et al., "Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment," Neoplasma, 2002, pp. 101-103, Volume 49, No. 2				
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, No. 4				

Examiner Signature	/Jehanne Sitton/	Date Considered	10/18/2010
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/582,705
		Filing Date	June 12, 2006
		First Named Inventor	John Foekens
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 3 of 6	Attorney Docket Number	47675-198	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GALFRE et al., "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , Colowick and Kaplan (editors-in-chief), Langone and Vunakis (editors), 1981, pp. 3-46, Volume 73, Immunochemical Techniques, Part B	
		GONZALGO et al., "Identification and Characterization of Differentially Methylated Regions of Genomic DNA by Methylation-sensitive Arbitrarily Primed PCR," <i>Cancer Research</i> , February 15, 1997, pp. 594-599, Volume 57	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), <i>Nucleic Acids Research</i> , 1997, pp. 2529-2531, Volume 25, No. 12	
		GOUGH et al., "Identification of the primary gene defect at the cytochrome P450 CYP2D locus," <i>Nature</i> , October 25, 1990, pp. 773-776, Volume 347, No. 6295	
		GREENLEE et al., "Cancer Statistics, 2000," <i>CA - A Cancer Journal for Clinicians</i> , January/February 2000, pp. 7-33, Volume 50, No. 1	
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," <i>BioEssays</i> , June 1994, pp. 431-436, Volume 16, No. 6	
		GUT et al., "DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry," <i>Molecular Biology: Current Innovations and Future Trends</i> , 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom	
		GUT et al., "A procedure for selection DNA alkylation and detection by mass spectrometry," <i>Nucleic Acids Research</i> , 1995, pp. 1367-1373, Volume 23, No. 8	
		HARBECK et al., "Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination," <i>Journal of Clinical Oncology</i> , February 15, 2002, pp. 1000-1007, Volume 20, No. 4	
		HEID et al., "Real Time Quantitative PCR," <i>Genome Research</i> , 1996, pp. 986-994, Volume 6	
		HERMAN et al., "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," September 1996, pp. 9821-9826, Volume 93	
		HOUSTON et al., "Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer," <i>British Journal of Cancer</i> , 1999, pp. 1220-1226, Volume 79, No. 7/8	
		JORDAN et al., "Chemoprevention of Breast Cancer: A Model for Change," <i>Journal of Clinical Oncology</i> , January 1, 2002, pp. 1-3, Volume 20, No. 1	
		JORDAN et al., "Tamoxifen, Raloxifene, and the Prevention of Breast Cancer," <i>Endocrine Reviews</i> , 1999, pp. 253-278, Volume 20, No. 3	
		KANG et al., "Methylation in the p53 Promoter Is a Supplementary Route to Breast Carcinogenesis: Correlation between CpG Methylation in the p53 Promoter and the Mutation of the p53 Gene in the Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma," <i>Laboratory Investigation</i> , 2001, pp. 573-579, Volume 81, No. 4	
		KARAS et al., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons," <i>Analytical Chemistry</i> , October 15, 1988, pp. 2299-2301, Volume 60, No. 20	

Examiner Signature	/Jehanne Sitton/	Date	10/18/2010
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/582,705
		Filing Date	June 12, 2006
		First Named Inventor	John Foekens
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 4 of 6	Attorney Docket Number	47675-198	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KIM et al., "Hypermethylation of RASSF1A Promoter Is Associated with the Age at Starting Smoking and a Poor Prognosis in Primary Non-Small Cell Lung Cancer," Cancer Research, July 1, 2003, pp. 3743-3746, Volume 63	
		KOEHLER et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, August 7, 1975, pp. 495-497, Volume 256, No. 5517	
		KRUG et al., "First Strand cDNA Synthesis Primed with Oligo(dT)," Methods in Enzymology, 1987, pp. 316-325, Volume 152	
		KUZMIN et al., "Inactivation of RAS Association Domain Family 1A Gene in Cervical Carcinomas and the Role of Human Papillomavirus Infection," Cancer Research, April 15, 2003, pp. 1888-1893, Volume 63	
		LANCET, "Polychemotherapy for early breast cancer: an overview of the randomised trials [Early Breast Cancer Trialists' Cooperative Group]," September 19, 1998, pp. 930-942, Volume 352, No. 9132	
		LANCET, "Tamoxifen for early breast cancer: an overview of the randomised trials [Early Breast Cancer Trialists' Cooperative Group]," May 16, 1998, pp. 1451-1467, Volume 351, No. 9114	
		LAPIDUS et al., "Methylation of Estrogen and Progesterone Receptor Gene 5' CpG Islands Correlates with Lack of Estrogen and Progesterone Receptor Gene Expression in Breast Tumors," Clinical Cancer Research, May 1996, pp. 805-810, Volume 2	
		LÜCKE et al., "Inhibiting Mutations in the Transforming Growth Factor β Type 2 Receptor in Recurrent Human Breast Cancer," Cancer Research, January 15, 2001, pp. 482-485, Volume 61	
		MANSOUR et al., "Survival Advantage of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer: Ten-Year Analysis - An Intergroup Study," Journal of Clinical Oncology, November 1998, pp. 3486-3492, Volume 16, No. 11	
		MARTENS et al., "Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer," Breast Cancer Research and Treatment, June 3, 2003, p. S72, Volume 82, No. Supp. 1, abstract only	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region on the pS2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-264, Volume 157	
		MARTIN et al., "Involvement of DNA Methylation in the Control of the Expression of an Estrogen-Induced Breast-Cancer-Associated Protein (pS2) in Human Breast Cancers," Journal of Cellular Biochemistry, 1997, pp. 95-106, Volume 65	
		MEYERSON et al., "Identification of G1 Kinase Activity for cdk6, a Novel Cyclin D Partner," Molecular and Cellular Biology, March 1994, pp. 2077-2086, Volume 14, No. 3	
		OJALA et al., "mRNA differential display of gene expression in colonic carcinoma," Electrophoresis, June 2002, pp. 1667-1676, Volume 23, No. 11	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	

Examiner Signature	/Jehanne Sitton/	Date	10/18/2010
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/582,705		
		Filing Date	June 12, 2006		
		First Named Inventor	John Foekens		
		Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	5	of	6	Attorney Docket Number	47675-198

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OSBORNE, "Tamoxifen in the Treatment of Breast Cancer," New England Journal of Medicine, November 26, 1998, pp. 1609-1618, Volume 339, No. 22	
		OTTAVIANO et al., "Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cells," Cancer Research, May 15, 1994, pp. 2552-2555, Volume 54	
		PEI et al., "PRC17, a Novel Oncogene Encoding a Rab GTPase-activating Protein, Is Amplified in Prostate Cancer," Cancer Research, October 1, 2002, pp. 5420-5424, Volume 62	
		PICCART et al., "The EORTC-Breast Cancer Cooperative Group Clinical Research Programme in Early Breast Cancer," Recent Results in Cancer Research, 1998, pp. 447-452, Volume 152	
		RAMAN et al., "Compromised HOXA5 function can limit p53 expression in human breast tumors," Nature, June 22, 2000, pp. 974-978, Volume 405	
		REIN et al., "SURVEY and SUMMARY Identifying 5-methylcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 26, No. 10	
		RIBIERAS et al., "The pS2/TFF1 trefoil factor, from basic research to clinical applications," Biochimica et Biophysica Acta, July 19, 1998, pp. F61-F77, Volume 1378	
		RODRIGUES et al., "Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences," Current Drug Metabolism, June 2002, pp. 289-309, Volume 3, No. 3	
		SAKAI et al., "Prognostic Significance of β -Microseminoprotein mRNA Expression in Prostate Cancer," The Prostate, March 1, 1999, pp. 278-284, Volume 38, No. 4	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," PNAS, December 1977, pp. 5463-5467, Volume 74, No. 12	
		SCHAUSI et al., "Regulation of the Intronic Promoter of Rat Estrogen Receptor α Gene, Responsible for Truncated Estrogen Receptor Product-1 Expression," Endocrinology, July 2003, pp. 2845-2855, Volume 144, No. 7	
		SCHWARTZ et al., "pS2 Expression and Response to Hormonal Therapy in Patients with Advanced Breast Cancer," Cancer Research, January 15, 1991, pp. 624-628, Volume 51	
		STITES et al., "Clinical laboratory methods for detection of antigens and antibodies," <u>Basic and Clinical Immunology</u> , 7 th ed., 1991, pp. 217-262, Appleton & Lange, Norwalk, Conn.	
		SUZUKI et al., "Alcohol and Postmenopausal Breast Cancer Risk Defined by Estrogen and Progesterone Receptor Status: A Prospective Cohort Study," Journal of the National Cancer Institute, November 2, 2005, pp. 1601-1608, Volume 97, No. 21	
		TOYOTA et al., "Methylation profiling in acute myeloid leukemia," Blood, May 1, 2001, pp. 2823-2829, Volume 97, No. 9	
		UMBRICHT et al., "Hypermethylation of 14-3-3 σ (stratfin) is an early event in breast cancer," Oncogene, 2001, pp. 3348-3353, Volume 20	
		VAN DER KROL et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," BioTechniques, November-December 1988, pp. 958-976, Volume 6, No. 10	
Examiner Signature	/Jehanne Sitton/		Date 10/18/2010 Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/582,705
				Filing Date	June 12, 2006
				First Named Inventor	John Foekens
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	47675-198
Sheet	6	of	6		

[illegible]

Examiner Signature	/Jehanne Sitton/	Date Considered	10/18/2010
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/